Skip to content
MARKETS / NASDAQ / HTFL
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Heartflow, Inc. HTFL

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$176.0M
▲ 39.9% YoY
$-116.8M
$-59.0M
In brief

What this company does

Heartflow, Inc. provides software and artificial intelligence for the non-invasive diagnosis and management of coronary artery disease. As of December 31, 2025, its Heartflow Platform had been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. As of December 31, 2025, it had 843 full-time employees globally. It has developed three software products under the Heartflow Platform that provide physicians with insights to diagnose and manage CAD. The Heartflow RoadMap Analysis provides an anatomic visualization of the patient's coronary anatomy based on CCTA images. Heartflow FFRCT Analysis consists of a patient-specific, interactive 3D anatomical reconstruction of the coronary anatomy that calculates blood flow and identifies clinically significant CAD, defined as a fractional flow reserve value of 0.80 or below, at every point in the major coronary arteries. The Heartflow Plaque Analysis provides a 3D assessment of a patient's coronary plaque, including a characterization of plaque types and quantification of plaque volumes at every point in the major coronary arteries.

Written from the business description in Heartflow, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.

Growth
USD 176.0M
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 176.0 · Net income -116.8
80M160M-40M-80M202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−66 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -36.4% · Net -66.3%
-50%-100%202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -59.0
-40M-80M202320242025
Net buybacks $ Dividends $
FY2023 · Dividends — · Net buybacks -361000.0
-2000002023

Total assetsUSD 359.5M
EquityUSD 300.6M
CashUSD 44.8M
Current ratio5.20×

Equity funds 84% of total assets.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023
Revenue $B0.20.10.1
Operating income $B−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1
Income tax $B−0.00.00.0
Net income $B−0.1−0.1−0.1
Free cash flow $B−0.1−0.1−0.1
EPS, diluted $−3.17−17.98−25.32
Dividend / sh $···
Payout %···
ROE %···
Shares out B0.090.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 13 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 82 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2023

Share this section

Download image